Denmark-based Dawn Health raises €21.5 million (US$25.6 million) in a growth funding round to develop AI-driven, patient-centric, regulatory-grade digital commercial and clinical companion applications for pharma companies.
Cipio Partners led the funding round with participation from Chr. Augustinus Fabrikker (CAF), the Export and Investment Fund of Denmark (EIFO), and Trifork Labs.
Led by CEO Alexander Mandix Hansen, Dawn Health is a global digital health startup partnering with pharmaceutical companies to co-create and scale regulated digital solutions that support patient care and real-world use. Dawn Health designs and delivers AI-enabled and connected health products, including Software as a Medical Device (SaMD), that support patients, healthcare professionals, and pharma teams across clinical trials, real-world evidence generation, and commercial programs.
Its patient-centric solutions help people living with chronic conditions stay engaged in their care, enable compliant data collection beyond the clinic, and support efficient deployment of digital products.
“Dawn Health stands out as a company with a very strong product foundation, deep regulatory expertise, and trusted, long-standing relationships with global pharma leaders,” said Dr. Ansgar Kirchheim, Partner at Cipio Partners.
“We see a clear opportunity to support Dawn Health in further scaling its SaaS offer and expanding even more into the clinical trial space, where digital and data-driven solutions are becoming increasingly critical. We are excited to partner with Dawn Health’s great team on the next phase of growth.”
Digital health companies have secured more than $170 billion in venture capital funding to date, according to the latest funding data compiled by Digital Health Funding. More recently, Pasito, a provider of AI-powered personalized employee health benefits and retirement benefits solutions, raised $21 million in Series A funding.